Lenvatinib
- Generic Name
- Lenvatinib
- Brand Names
- Lenvima 10, Kisplyx, Lenvima
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19ClN4O4
- CAS Number
- 417716-92-8
- Unique Ingredient Identifier
- EE083865G2
- Background
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular ...
- Indication
Lenvatinib is indicated for the treatment of the following cancerous conditions:
Differentiated Thyroid Cancer (DTC)
Renal Cell Carcinoma (RCC)
Hepatocellular Carcinoma (HCC)
Endometrial Carcinoma
- Associated Conditions
- Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)
- Associated Therapies
- -
Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-04-23
- Last Posted Date
- 2022-11-10
- Lead Sponsor
- Emory University
- Target Recruit Count
- 4
- Registration Number
- NCT03506048
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- Conditions
- Interventions
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 3500
- Registration Number
- NCT03486873
- Locations
- 🇧🇷
Hospital de Clínicas de Passo Fundo ( Site 1025), Passo Fundo, Rio Grande Do Sul, Brazil
🇨🇳The Affiliated Cancer Hospital of Guizhou Medical University ( Site 3498), Guiyang, Guizhou, China
🇮🇱ZIV Medical Center-Hematology Institute ( Site 2061), Safed, Israel
Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03433703
- Locations
- 🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
🇺🇸University of Louisville, Louisville, Kentucky, United States
🇺🇸California Liver Research Institute, Pasadena, California, United States
A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03418922
- Locations
- 🇯🇵
Eisai Trial Site 3, Kawasaki, Kanagawa, Japan
🇯🇵Eisai Trial Site 1, Kashiwa, Chiba, Japan
🇯🇵Eisai Trial Site 6, Iizuka, Fukuoka, Japan
Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)
- Conditions
- Interventions
- First Posted Date
- 2017-10-27
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Yousef Zakharia
- Target Recruit Count
- 11
- Registration Number
- NCT03324373
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies
- Conditions
- Interventions
- First Posted Date
- 2017-10-25
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 24
- Registration Number
- NCT03321630
- Locations
- 🇺🇸
The Mount Sinai Hospital, New York, New York, United States
🇺🇸NYU Langone Health, New York, New York, United States
Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma
- Conditions
- Interventions
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 60
- Registration Number
- NCT03313206
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2024-11-28
- Target Recruit Count
- 20
- Registration Number
- NCT03290079
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT03245151
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Southern California Permanente Medical Group, Los Angeles, California, United States
Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 343
- Registration Number
- NCT03173560
- Locations
- 🇦🇺
Northern Cancer Institute, Saint Leonards, Saint Leonards, New South Wales, Australia
🇨🇿Nemocnice Na Bulovce, Prague, Czechia
🇺🇸Optimal Research, Honolulu, Hawaii, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.